SlideShare a Scribd company logo
1 of 21
Download to read offline
1
• For USFDA
 Introduction
 Constitution
 Mission
 Organization
 What USFDA regulates?
 What USFDA does not regulates?
 References
2
• For WHO
 Introduction
 Governance of WHO
 History
 Resource and planning
 Role in public health
 WHO agenda
 Its people and offices
 References
3
4
U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
1-888-INFO-FDA (1-888-463-6332)
• The United States Food and Drug Administration (best
known as the FDA) is an agency within the U.S. Public
Health Service, which is a part of the Department of Health
and Human Services.
• FDA ensures that the food we eat is safe and wholesome,
that the cosmetics we use won’t harm us, and that
medicines, medical devices, and radiation emitting
consumer products such as microwave ovens are safe and
effective.
• FDA also oversees food and drugs for pet and farm animals.
Authorized by Congress to enforce the Federal Food, Drug,
and Cosmetic Act and several other public health laws, the
agency monitors the manufacture, import ,transport
,storage ,and sale of $1 trillion worth of goods annually.
5
• USFDA has over 9000 employees, located in 167 U.S.
cities. Among its staff, FDA has chemists, microbiologist,
and other scientists, as well as investigators and
inspectors who visit 16000 facilities a year as part of their
oversight of the business that FDA regulates.
6
• To promote the public health by promptly and efficiently
reviewing clinical research and taking appropriate action
on the marketing of regulated products in a timely manner.
• With respect to such products, protect the public health by
ensuring that the food are safe, wholesome, sanitary, and
properly labeled; human and veterinary drugs are safe and
effective; there is reasonable assurance of the safety and
effectiveness of devices intended for human use;
cosmetics are safe and properly labeled, and public health
and safety are protected from the electronic product
radiation.
• Participates through appropriate process with
representatives of other countries to reduce the burden of
regulation, harmonize regulatory requirements, and
achieve appropriate reciprocal arrangements.
7
• Centre for Biologics Evaluation and Research ( CBER )
• Centre for Devices and Radiological Health ( CDRH )
• Centre for Drug Evaluation and Research ( CDER )
• Centre for Food Safety and Applied Nutrition ( CFSAN )
• Centre for veterinary Medicine ( CVM )
• National Centre for Toxicological Research ( NCTR )
• Office of Chief Council ( OCC )
• Office of Commissioner ( OC )
• Office of Regulatory Affairs ( ORA )
8
9
GOVERNANCE
Governance takes place through the World Health Assembly, which is the
supreme decision-making body; and the Executive Board, which gives effect
to the decisions and policies of the Health Assembly. The Organization is
headed by the Director-General, who is appointed by the Health Assembly
on the nomination of the Executive Board.
1) World Health Assembly
The World Health Assembly is the decision-making body of WHO. It is
attended by delegations from all WHO Member States and focuses on a
specific health agenda prepared by the Executive Board. The main functions
of the World Health Assembly are to determine the policies of the
Organization, appoint the Director-General, supervise financial policies, and
review and approve the proposed programme budget.
2) Executive Board
The Executive Board is composed of 34 technically qualified members
elected for three-year terms.
3) Director-General
Dr Tedros Adhanom Ghebreyesus is the Director-General of WHO, elected
by a vote of Member States at the World Health Assembly on 23 May 2017.
• Biologics
• Product and Manufacturing establishment Licensing
• Safety to nation’s blood supply
• Research to establish product standards and develop
improved testing's methods
• Cosmetics
• Labeling
• Drugs
• Product approvals
• OTC and prescription drug labeling
• Drug manufacturing standards
• Foods
• Safety of all food products ( except meat and poultry)
10
• Radiation-Emitting Electronic Products
• Radiation safety performance standards for microwave
ovens, television receivers, diagnostic x-rays equipment,
cabinet x-ray system ( such as baggage x-rays at
airports ), Laser products, ultrasonic therapy equipment,
mercury vapour lamps
• Veterinary products
11
• Advertising
• Alcohol
• Consumer Products
• Drugs of Abuse
• Health Insurance
• Meat and Poultry
• Pesticides
• Restaurants and Grocery Stores
• Water
12
13
• WHO is the directing and coordinating authority for
health within the United Nations system.
• It is responsible for providing leadership on global health
matters, shaping the health research agenda, setting
norms and standards, articulating evidence-based
policy options, providing technical support to countries
and monitoring and assessing health trends.
• In the 21st century, health is a shared responsibility,
involving equitable access to essential care and
collective defense against transnational threats.
14
• When diplomats met to form the United Nations in 1945,
one of the things they discussed was setting up a global
health organization.
• WHO began when their Constitution came into
force on 7 April 1948 – a date now celebrated
every year as World Health Day. They are now
more than 7000 people from more than 150
countries working in 150 country offices, in 6
regional offices and at headquarters in Geneva.
15
• The framework for the financial resources and expenditures of
WHO is derived from the 11th General Programme of Work,
which covers the period 2006-2015.
• From 2008, a medium-term strategic plan will form the
framework for WHO's results-based management. The six-year
plan — for 2008 to 2013 — will cover three biennial budget
periods, starting with the biennium 2008-2009.
• The strategic plan and its first Programme Budget for 2008-
2009 were adopted by the World Health Assembly in May
2007.
16
• Providing leadership on matters critical to health and
engaging in partnerships where joint action is needed;
• Shaping the research agenda and stimulating the
generation, translation and dissemination of
valuable knowledge;
• Setting norms and standards and promoting and
monitoring their implementation;
• Providing technical support, catalyzing change, and
building sustainable institutional capacity; and
• Monitoring the health situation and assessing health
trends.
• These core functions are set out in the 11th General
Programme of Work, which provides the framework for
organization-wide programme of work, budget, resources
and results. Entitled "Engaging for health", it covers the 10-
year period from 2006 to 2015.
17
• Promoting development
• Fostering health security
• Strengthening health systems
• Harnessing research, information and evidence
• Enhancing partnerships
• Improving performance
18
• More than 8000 people from more than 150 countries
work for the Organization in 147 country offices, six
regional offices and at the headquarters in Geneva,
Switzerland.
• In addition to medical doctors, public health specialists,
scientists and epidemiologists.
• WHO staff include people trained to manage
administrative, financial, and information systems, as
well as experts in the fields of health statistics,
economics and emergency relief.
19
 Dr. B.S. Kuchekar, Mr. A.M. Khadatare, FORENSIC
PHARMACY 7th Edition August 2007 Published By- NIRALI
PRAKASHAN ,PP-17.8 to 17.11, 17.25 to 17.28
 Sachin C. Itkar, PHARMACEUTICAL MANAGEMENT 3rd
Edition May 2007 Published By- NIRALI PRAKASHAN ,PP-
18.1 to 18.4 , 18.21 to 18.24
 www.fda.gov
 www.who.int
 www.medicinenet.com
 www.hhs.gov
 www.wikepedia.com
20
USFDA Functions and Organization

More Related Content

What's hot

Approval and Application Process involved in Investigational New Drug (IND)
Approval and Application Process involved in Investigational New Drug (IND)Approval and Application Process involved in Investigational New Drug (IND)
Approval and Application Process involved in Investigational New Drug (IND)Nipun Gupta
 
Post marketing surveillance
Post marketing surveillancePost marketing surveillance
Post marketing surveillanceGaurav Sharma
 
Regulatory affairs, Regulatory requirements for drug approval.pptx
Regulatory affairs, Regulatory  requirements for drug  approval.pptxRegulatory affairs, Regulatory  requirements for drug  approval.pptx
Regulatory affairs, Regulatory requirements for drug approval.pptxPawanDhamala1
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)Manish Rajput
 
central and state Regulatory bodies in India
central and state Regulatory bodies in Indiacentral and state Regulatory bodies in India
central and state Regulatory bodies in Indiasonaliph
 
ICH & WHO GUIDELINES ON validation
ICH & WHO GUIDELINES ON validationICH & WHO GUIDELINES ON validation
ICH & WHO GUIDELINES ON validationSACHIN C P
 
Generic drug product development
Generic drug product developmentGeneric drug product development
Generic drug product developmentBashant Kumar sah
 
Regulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan pptRegulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan pptsandeep bansal
 
Us registration for foreign drugs
Us registration for foreign drugsUs registration for foreign drugs
Us registration for foreign drugsNiva Rani Gogoi
 
Therapeutic Good Administration
Therapeutic Good AdministrationTherapeutic Good Administration
Therapeutic Good AdministrationSAKSHI YADAV
 
Ich guidelines Seminar ( Efficacy & Multidisciplinary)
Ich guidelines Seminar ( Efficacy & Multidisciplinary)Ich guidelines Seminar ( Efficacy & Multidisciplinary)
Ich guidelines Seminar ( Efficacy & Multidisciplinary)VivekWagh13
 

What's hot (20)

Quality by Design ( QbD )
Quality by Design ( QbD )Quality by Design ( QbD )
Quality by Design ( QbD )
 
Documentation in Pharmaceutical Industry
Documentation in Pharmaceutical IndustryDocumentation in Pharmaceutical Industry
Documentation in Pharmaceutical Industry
 
Approval and Application Process involved in Investigational New Drug (IND)
Approval and Application Process involved in Investigational New Drug (IND)Approval and Application Process involved in Investigational New Drug (IND)
Approval and Application Process involved in Investigational New Drug (IND)
 
Post marketing surveillance
Post marketing surveillancePost marketing surveillance
Post marketing surveillance
 
Regulatory affairs, Regulatory requirements for drug approval.pptx
Regulatory affairs, Regulatory  requirements for drug  approval.pptxRegulatory affairs, Regulatory  requirements for drug  approval.pptx
Regulatory affairs, Regulatory requirements for drug approval.pptx
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)
 
central and state Regulatory bodies in India
central and state Regulatory bodies in Indiacentral and state Regulatory bodies in India
central and state Regulatory bodies in India
 
Code of Federal Regulations
Code of Federal RegulationsCode of Federal Regulations
Code of Federal Regulations
 
CTD and eCTD
CTD and eCTDCTD and eCTD
CTD and eCTD
 
Nda
NdaNda
Nda
 
ICH & WHO GUIDELINES ON validation
ICH & WHO GUIDELINES ON validationICH & WHO GUIDELINES ON validation
ICH & WHO GUIDELINES ON validation
 
GMP AND cGMP CONSIDERATIONS
GMP AND cGMP CONSIDERATIONSGMP AND cGMP CONSIDERATIONS
GMP AND cGMP CONSIDERATIONS
 
ANDA
ANDAANDA
ANDA
 
Generic drug product development
Generic drug product developmentGeneric drug product development
Generic drug product development
 
Supac
Supac Supac
Supac
 
Regulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan pptRegulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan ppt
 
Us registration for foreign drugs
Us registration for foreign drugsUs registration for foreign drugs
Us registration for foreign drugs
 
Outsourcing BA and BE to CRO
Outsourcing BA and BE to CROOutsourcing BA and BE to CRO
Outsourcing BA and BE to CRO
 
Therapeutic Good Administration
Therapeutic Good AdministrationTherapeutic Good Administration
Therapeutic Good Administration
 
Ich guidelines Seminar ( Efficacy & Multidisciplinary)
Ich guidelines Seminar ( Efficacy & Multidisciplinary)Ich guidelines Seminar ( Efficacy & Multidisciplinary)
Ich guidelines Seminar ( Efficacy & Multidisciplinary)
 

Similar to USFDA Functions and Organization

regulaotryauthorities-160426054815.pdf
regulaotryauthorities-160426054815.pdfregulaotryauthorities-160426054815.pdf
regulaotryauthorities-160426054815.pdfVhuii
 
Regulatory authorities (US-FDA, WHO and ICH)
Regulatory authorities (US-FDA, WHO and ICH)Regulatory authorities (US-FDA, WHO and ICH)
Regulatory authorities (US-FDA, WHO and ICH)Sagar Savale
 
MERTON SMITHde Djerba final
MERTON SMITHde Djerba finalMERTON SMITHde Djerba final
MERTON SMITHde Djerba finalMerton Smith
 
Medical & Healthcare Products Regulatory Agency (MHRA)
Medical & Healthcare Products Regulatory Agency (MHRA)Medical & Healthcare Products Regulatory Agency (MHRA)
Medical & Healthcare Products Regulatory Agency (MHRA)PriyalBagwe
 
Assignment on pharmacovigilance
Assignment on pharmacovigilanceAssignment on pharmacovigilance
Assignment on pharmacovigilanceDeepak Kumar
 
health system of india
health system of indiahealth system of india
health system of indiapradipta008
 
Role of who in pharmaceutical management
Role of who in pharmaceutical managementRole of who in pharmaceutical management
Role of who in pharmaceutical managementANANT NAG
 
4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdfASSAM DOWN TOWN UNIVERSITY
 
E&L workshop Session 1 for the identificationdf
E&L workshop Session 1 for the identificationdfE&L workshop Session 1 for the identificationdf
E&L workshop Session 1 for the identificationdfThippaniRameshVarma
 
Drug Regulatory Agencies.
 Drug Regulatory Agencies. Drug Regulatory Agencies.
Drug Regulatory Agencies.Priyanka Chakote
 
CGMP GUIDELINES.pptx
CGMP GUIDELINES.pptxCGMP GUIDELINES.pptx
CGMP GUIDELINES.pptxGauriBorude2
 

Similar to USFDA Functions and Organization (20)

regulaotryauthorities-160426054815.pdf
regulaotryauthorities-160426054815.pdfregulaotryauthorities-160426054815.pdf
regulaotryauthorities-160426054815.pdf
 
Regulatory authorities (US-FDA, WHO and ICH)
Regulatory authorities (US-FDA, WHO and ICH)Regulatory authorities (US-FDA, WHO and ICH)
Regulatory authorities (US-FDA, WHO and ICH)
 
Regulatory bodies & CRO
Regulatory bodies & CRORegulatory bodies & CRO
Regulatory bodies & CRO
 
MERTON SMITHde Djerba final
MERTON SMITHde Djerba finalMERTON SMITHde Djerba final
MERTON SMITHde Djerba final
 
Medical & Healthcare Products Regulatory Agency (MHRA)
Medical & Healthcare Products Regulatory Agency (MHRA)Medical & Healthcare Products Regulatory Agency (MHRA)
Medical & Healthcare Products Regulatory Agency (MHRA)
 
Assignment on pharmacovigilance
Assignment on pharmacovigilanceAssignment on pharmacovigilance
Assignment on pharmacovigilance
 
MHRA.pptx
MHRA.pptxMHRA.pptx
MHRA.pptx
 
health system of india
health system of indiahealth system of india
health system of india
 
Ich
IchIch
Ich
 
Role of who in pharmaceutical management
Role of who in pharmaceutical managementRole of who in pharmaceutical management
Role of who in pharmaceutical management
 
Regulatory agencies
Regulatory agenciesRegulatory agencies
Regulatory agencies
 
Ich guidelines ppt
Ich guidelines pptIch guidelines ppt
Ich guidelines ppt
 
Tài liệu hướng dẫn của WHO về GACP cho cây thuốc (english version)
Tài liệu hướng dẫn của WHO về  GACP cho cây thuốc (english version)Tài liệu hướng dẫn của WHO về  GACP cho cây thuốc (english version)
Tài liệu hướng dẫn của WHO về GACP cho cây thuốc (english version)
 
Usfda ppn
Usfda ppnUsfda ppn
Usfda ppn
 
Roshan (1)
Roshan (1)Roshan (1)
Roshan (1)
 
4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf
 
Madhu k s
Madhu k s Madhu k s
Madhu k s
 
E&L workshop Session 1 for the identificationdf
E&L workshop Session 1 for the identificationdfE&L workshop Session 1 for the identificationdf
E&L workshop Session 1 for the identificationdf
 
Drug Regulatory Agencies.
 Drug Regulatory Agencies. Drug Regulatory Agencies.
Drug Regulatory Agencies.
 
CGMP GUIDELINES.pptx
CGMP GUIDELINES.pptxCGMP GUIDELINES.pptx
CGMP GUIDELINES.pptx
 

More from Suvarta Maru

case study - Urinary tract infection with diabetes mellitus
case study - Urinary tract infection with  diabetes mellitus case study - Urinary tract infection with  diabetes mellitus
case study - Urinary tract infection with diabetes mellitus Suvarta Maru
 
WORLD HEALTH ORGANIZATION ( WHO )
WORLD HEALTH ORGANIZATION ( WHO )WORLD HEALTH ORGANIZATION ( WHO )
WORLD HEALTH ORGANIZATION ( WHO )Suvarta Maru
 
Various approachesto drug discovery
Various approachesto drug discoveryVarious approachesto drug discovery
Various approachesto drug discoverySuvarta Maru
 
Schedules of drugs
Schedules of drugsSchedules of drugs
Schedules of drugsSuvarta Maru
 
Quinolone antibacterials
Quinolone antibacterialsQuinolone antibacterials
Quinolone antibacterialsSuvarta Maru
 
Protein binding of drug
Protein binding of drugProtein binding of drug
Protein binding of drugSuvarta Maru
 
Preclinical trials
Preclinical trialsPreclinical trials
Preclinical trialsSuvarta Maru
 
Poison AND treatment
Poison AND treatmentPoison AND treatment
Poison AND treatmentSuvarta Maru
 
Pharmacovigilance STUDY
Pharmacovigilance STUDYPharmacovigilance STUDY
Pharmacovigilance STUDYSuvarta Maru
 
Pharmacoeconomics STUDY
Pharmacoeconomics STUDYPharmacoeconomics STUDY
Pharmacoeconomics STUDYSuvarta Maru
 
OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)
OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)
OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)Suvarta Maru
 
NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)
NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)
NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)Suvarta Maru
 
Non linear kinetics
Non linear kineticsNon linear kinetics
Non linear kineticsSuvarta Maru
 

More from Suvarta Maru (20)

case study - Urinary tract infection with diabetes mellitus
case study - Urinary tract infection with  diabetes mellitus case study - Urinary tract infection with  diabetes mellitus
case study - Urinary tract infection with diabetes mellitus
 
WORLD HEALTH ORGANIZATION ( WHO )
WORLD HEALTH ORGANIZATION ( WHO )WORLD HEALTH ORGANIZATION ( WHO )
WORLD HEALTH ORGANIZATION ( WHO )
 
Various approachesto drug discovery
Various approachesto drug discoveryVarious approachesto drug discovery
Various approachesto drug discovery
 
US FDA
US FDA US FDA
US FDA
 
Toxicity slides
Toxicity slidesToxicity slides
Toxicity slides
 
TGA & MHRA
TGA & MHRATGA & MHRA
TGA & MHRA
 
Thermal analysis
Thermal analysisThermal analysis
Thermal analysis
 
Stroke study
Stroke studyStroke study
Stroke study
 
Schedules of drugs
Schedules of drugsSchedules of drugs
Schedules of drugs
 
Schedule m
Schedule  m Schedule  m
Schedule m
 
Quinolone antibacterials
Quinolone antibacterialsQuinolone antibacterials
Quinolone antibacterials
 
Protein binding of drug
Protein binding of drugProtein binding of drug
Protein binding of drug
 
Preclinical trials
Preclinical trialsPreclinical trials
Preclinical trials
 
Poison AND treatment
Poison AND treatmentPoison AND treatment
Poison AND treatment
 
Pharmacovigilance STUDY
Pharmacovigilance STUDYPharmacovigilance STUDY
Pharmacovigilance STUDY
 
Pharmacoeconomics STUDY
Pharmacoeconomics STUDYPharmacoeconomics STUDY
Pharmacoeconomics STUDY
 
OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)
OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)
OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)
 
NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)
NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)
NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)
 
Non linear kinetics
Non linear kineticsNon linear kinetics
Non linear kinetics
 
New drug approval
New drug approvalNew drug approval
New drug approval
 

Recently uploaded

ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxiammrhaywood
 
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxEPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxRaymartEstabillo3
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxNirmalaLoungPoorunde1
 
DATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersDATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersSabitha Banu
 
MARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized GroupMARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized GroupJonathanParaisoCruz
 
History Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptxHistory Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptxsocialsciencegdgrohi
 
Presiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsPresiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsanshu789521
 
Meghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentMeghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentInMediaRes1
 
Hierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of managementHierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of managementmkooblal
 
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTiammrhaywood
 
भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,Virag Sontakke
 
How to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxHow to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxmanuelaromero2013
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxSayali Powar
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdfssuser54595a
 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentInMediaRes1
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxpboyjonauth
 
CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxGaneshChakor2
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptxVS Mahajan Coaching Centre
 
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfSumit Tiwari
 

Recently uploaded (20)

ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
 
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxEPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptx
 
DATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersDATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginners
 
MARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized GroupMARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized Group
 
History Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptxHistory Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptx
 
Presiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsPresiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha elections
 
Meghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentMeghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media Component
 
Hierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of managementHierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of management
 
9953330565 Low Rate Call Girls In Rohini Delhi NCR
9953330565 Low Rate Call Girls In Rohini  Delhi NCR9953330565 Low Rate Call Girls In Rohini  Delhi NCR
9953330565 Low Rate Call Girls In Rohini Delhi NCR
 
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
 
भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,
 
How to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxHow to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptx
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media Component
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptx
 
CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptx
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
 
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
 

USFDA Functions and Organization

  • 1. 1
  • 2. • For USFDA  Introduction  Constitution  Mission  Organization  What USFDA regulates?  What USFDA does not regulates?  References 2
  • 3. • For WHO  Introduction  Governance of WHO  History  Resource and planning  Role in public health  WHO agenda  Its people and offices  References 3
  • 4. 4 U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 1-888-INFO-FDA (1-888-463-6332)
  • 5. • The United States Food and Drug Administration (best known as the FDA) is an agency within the U.S. Public Health Service, which is a part of the Department of Health and Human Services. • FDA ensures that the food we eat is safe and wholesome, that the cosmetics we use won’t harm us, and that medicines, medical devices, and radiation emitting consumer products such as microwave ovens are safe and effective. • FDA also oversees food and drugs for pet and farm animals. Authorized by Congress to enforce the Federal Food, Drug, and Cosmetic Act and several other public health laws, the agency monitors the manufacture, import ,transport ,storage ,and sale of $1 trillion worth of goods annually. 5
  • 6. • USFDA has over 9000 employees, located in 167 U.S. cities. Among its staff, FDA has chemists, microbiologist, and other scientists, as well as investigators and inspectors who visit 16000 facilities a year as part of their oversight of the business that FDA regulates. 6
  • 7. • To promote the public health by promptly and efficiently reviewing clinical research and taking appropriate action on the marketing of regulated products in a timely manner. • With respect to such products, protect the public health by ensuring that the food are safe, wholesome, sanitary, and properly labeled; human and veterinary drugs are safe and effective; there is reasonable assurance of the safety and effectiveness of devices intended for human use; cosmetics are safe and properly labeled, and public health and safety are protected from the electronic product radiation. • Participates through appropriate process with representatives of other countries to reduce the burden of regulation, harmonize regulatory requirements, and achieve appropriate reciprocal arrangements. 7
  • 8. • Centre for Biologics Evaluation and Research ( CBER ) • Centre for Devices and Radiological Health ( CDRH ) • Centre for Drug Evaluation and Research ( CDER ) • Centre for Food Safety and Applied Nutrition ( CFSAN ) • Centre for veterinary Medicine ( CVM ) • National Centre for Toxicological Research ( NCTR ) • Office of Chief Council ( OCC ) • Office of Commissioner ( OC ) • Office of Regulatory Affairs ( ORA ) 8
  • 9. 9 GOVERNANCE Governance takes place through the World Health Assembly, which is the supreme decision-making body; and the Executive Board, which gives effect to the decisions and policies of the Health Assembly. The Organization is headed by the Director-General, who is appointed by the Health Assembly on the nomination of the Executive Board. 1) World Health Assembly The World Health Assembly is the decision-making body of WHO. It is attended by delegations from all WHO Member States and focuses on a specific health agenda prepared by the Executive Board. The main functions of the World Health Assembly are to determine the policies of the Organization, appoint the Director-General, supervise financial policies, and review and approve the proposed programme budget. 2) Executive Board The Executive Board is composed of 34 technically qualified members elected for three-year terms. 3) Director-General Dr Tedros Adhanom Ghebreyesus is the Director-General of WHO, elected by a vote of Member States at the World Health Assembly on 23 May 2017.
  • 10. • Biologics • Product and Manufacturing establishment Licensing • Safety to nation’s blood supply • Research to establish product standards and develop improved testing's methods • Cosmetics • Labeling • Drugs • Product approvals • OTC and prescription drug labeling • Drug manufacturing standards • Foods • Safety of all food products ( except meat and poultry) 10
  • 11. • Radiation-Emitting Electronic Products • Radiation safety performance standards for microwave ovens, television receivers, diagnostic x-rays equipment, cabinet x-ray system ( such as baggage x-rays at airports ), Laser products, ultrasonic therapy equipment, mercury vapour lamps • Veterinary products 11
  • 12. • Advertising • Alcohol • Consumer Products • Drugs of Abuse • Health Insurance • Meat and Poultry • Pesticides • Restaurants and Grocery Stores • Water 12
  • 13. 13
  • 14. • WHO is the directing and coordinating authority for health within the United Nations system. • It is responsible for providing leadership on global health matters, shaping the health research agenda, setting norms and standards, articulating evidence-based policy options, providing technical support to countries and monitoring and assessing health trends. • In the 21st century, health is a shared responsibility, involving equitable access to essential care and collective defense against transnational threats. 14
  • 15. • When diplomats met to form the United Nations in 1945, one of the things they discussed was setting up a global health organization. • WHO began when their Constitution came into force on 7 April 1948 – a date now celebrated every year as World Health Day. They are now more than 7000 people from more than 150 countries working in 150 country offices, in 6 regional offices and at headquarters in Geneva. 15
  • 16. • The framework for the financial resources and expenditures of WHO is derived from the 11th General Programme of Work, which covers the period 2006-2015. • From 2008, a medium-term strategic plan will form the framework for WHO's results-based management. The six-year plan — for 2008 to 2013 — will cover three biennial budget periods, starting with the biennium 2008-2009. • The strategic plan and its first Programme Budget for 2008- 2009 were adopted by the World Health Assembly in May 2007. 16
  • 17. • Providing leadership on matters critical to health and engaging in partnerships where joint action is needed; • Shaping the research agenda and stimulating the generation, translation and dissemination of valuable knowledge; • Setting norms and standards and promoting and monitoring their implementation; • Providing technical support, catalyzing change, and building sustainable institutional capacity; and • Monitoring the health situation and assessing health trends. • These core functions are set out in the 11th General Programme of Work, which provides the framework for organization-wide programme of work, budget, resources and results. Entitled "Engaging for health", it covers the 10- year period from 2006 to 2015. 17
  • 18. • Promoting development • Fostering health security • Strengthening health systems • Harnessing research, information and evidence • Enhancing partnerships • Improving performance 18
  • 19. • More than 8000 people from more than 150 countries work for the Organization in 147 country offices, six regional offices and at the headquarters in Geneva, Switzerland. • In addition to medical doctors, public health specialists, scientists and epidemiologists. • WHO staff include people trained to manage administrative, financial, and information systems, as well as experts in the fields of health statistics, economics and emergency relief. 19
  • 20.  Dr. B.S. Kuchekar, Mr. A.M. Khadatare, FORENSIC PHARMACY 7th Edition August 2007 Published By- NIRALI PRAKASHAN ,PP-17.8 to 17.11, 17.25 to 17.28  Sachin C. Itkar, PHARMACEUTICAL MANAGEMENT 3rd Edition May 2007 Published By- NIRALI PRAKASHAN ,PP- 18.1 to 18.4 , 18.21 to 18.24  www.fda.gov  www.who.int  www.medicinenet.com  www.hhs.gov  www.wikepedia.com 20